WO1995034262A1 - Traitement transdermique du paludisme - Google Patents
Traitement transdermique du paludisme Download PDFInfo
- Publication number
- WO1995034262A1 WO1995034262A1 PCT/US1995/007696 US9507696W WO9534262A1 WO 1995034262 A1 WO1995034262 A1 WO 1995034262A1 US 9507696 W US9507696 W US 9507696W WO 9534262 A1 WO9534262 A1 WO 9534262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimalarial
- composition
- mice
- com
- compound
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title abstract description 15
- 239000003430 antimalarial agent Substances 0.000 claims abstract description 25
- 239000013543 active substance Substances 0.000 claims abstract description 20
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 229960002521 artenimol Drugs 0.000 claims description 8
- 229930016266 dihydroartemisinin Natural products 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229960000981 artemether Drugs 0.000 claims description 7
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims description 7
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 3
- 230000000078 anti-malarial effect Effects 0.000 claims 17
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims 4
- 229960002970 artemotil Drugs 0.000 claims 4
- BJDCWCLMFKKGEE-HVDUHBCDSA-N dihydroartemisinin group Chemical group C[C@@]12OO[C@]34[C@@H](CC1)[C@@H](CC[C@H]3[C@H](C(O[C@@H]4O2)O)C)C BJDCWCLMFKKGEE-HVDUHBCDSA-N 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 abstract description 5
- 229940033495 antimalarials Drugs 0.000 abstract description 4
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 32
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 10
- 229960004191 artemisinin Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229930101531 artemisinin Natural products 0.000 description 8
- UVNHKOOJXSALHN-ILQPJIFQSA-N artelinic acid Chemical compound O([C@@H]1[C@H](C)[C@@H]2CC[C@H]([C@@H]3CC[C@]4(C)O[C@H]([C@]23OO4)O1)C)CC1=CC=C(C(O)=O)C=C1 UVNHKOOJXSALHN-ILQPJIFQSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 208000009182 Parasitemia Diseases 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 5
- 241000224016 Plasmodium Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- -1 methoxy, ethoxy, propoxy Chemical group 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 3
- 229960004991 artesunate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 0 C[C@@](*OC1)([C@](*)(CCC(*)(*)[C@@]2(CC3)*=C)[C@@]12OO[C@@]3(N)OCN)C=* Chemical compound C[C@@](*OC1)([C@](*)(CCC(*)(*)[C@@]2(CC3)*=C)[C@@]12OO[C@@]3(N)OCN)C=* 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 150000005215 alkyl ethers Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- DLDAUVZOFWOFKP-JBPNRQLNSA-M sodium artelinate Chemical compound [Na+].O([C@@H]1[C@H](C)[C@@H]2CC[C@H]([C@@H]3CC[C@@]4(C)O[C@H]([C@]23OO4)O1)C)CC1=CC=C(C([O-])=O)C=C1 DLDAUVZOFWOFKP-JBPNRQLNSA-M 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 2
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930191701 arteannuin Natural products 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229910052700 potassium Chemical group 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 230000001445 schizonticidal effect Effects 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZISJLHQNEVGTIU-RFEYTNPVSA-M sodium 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoate Chemical compound [Na+].C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC([O-])=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 ZISJLHQNEVGTIU-RFEYTNPVSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to the prophylactic protection from and treatment of local and systemic effects of Plasmodium species which cause malaria by transdermal administration of artelinic acid or an analog thereof using artelinic acid and analogues thereof.
- Malaria is the most prevalent infectious disease on this planet. The disease is endemic throughout the tropics and the warmer parts of the temperate zone. Providing prophylaxis and treatment of large numbers of persons in warm climates where poverty is common and medical facilities are minimal presents particular problems for the clinician. Methods of treatment that require minimal expense and equipment for administration of antimalarial agents are needed if appropriate treatment of large populations is to become a reality.
- artelinic acid and its analogues for treatment of malaria.
- usual methods of administration for systemic effects such as oral or parenteral administration of the artelinic acid analogues has presented problems, since side effects seen with systemic administration are sometimes severe.
- first-pass metabolism such as occurs when medications are given orally may result in failure of the active agent to reach the target tissue.
- U.S. Patent 4,978,676 teaches topical administration of artemisinin derivatives for treatment of cutaneous conditions such as psoriasis, tumors, and untoward responses to ltravio- let light. That patent teaches topical administration of artemisinin, dihydroartemisinin, its semisyntheticderivatives, and synthetic analogues of the formula:
- R is a member selected from the group consisting of
- R' is a member selected from the groups consisting of 0 0 0 0 0
- the administration of agents which are effective against malaria using means which are inexpensive and do not require use of highly trained medical personnel for administration of the therapeutics is much needed.
- the administration of antimalarials transdermally as taught herein provides many advantages for treatment of large populations.
- the use of patch technology, a more preferred embodiment of the invention, makes it possible to treat large populations at low cost by non-invasive means.
- the patch provides active agents on solid supports.
- the supports with the active agents may advanta ⁇ geously be packaged in such a way that small bandages with water-proof backing having extensions with adhesives for attachment to the skin are packaged with a protective covering over the bandage portion containing the active agent. The protective covering is easily removed when the bandages are to be used.
- the active agents used by the inventive method are artemisinin-type antimalarials which are effective when administered at dosages of about 0.1 mg/kg to 60 mg/kg in mammals. In larger mammals such as man, the dosage is about 0.1 mg/kg to 30 mg/kg in the patc .
- the antimalarial agents are administered transdermally to provide systemic response. Thus administered the active agents are useful for effecting both prophylaxis and treatment of malaria.
- Artemisinin and artesunate have been known as antimalarial drugs.
- administration of this class of compounds has presented problems since the artemisinin is poorly soluble in water or oil, and the artesunate has a short plasma half-life when given parenterally.
- the administration of artemisinin- like compounds by the application of patches having the active agents on a support such as gauze or cellulose now provides an inexpensive and easy means of application.
- the use of patches allows administration of controlled dosage. Agents which are not readily absorbed into the body from the intestinal tract or might be destroyed chemically or enzy ati- cally if administered by mouth can be administered effectively using the methods of the invention.
- the invention was tested using mice infected with Plasmodium berqhei, a widely accepted model for testing effectiveness against infection with the malaria-causing Plasmodium species in mammals.
- Compunds for used in the method of the invention include those of the structure:
- R' The compounds having an acid moiety on substituent R' appear to be less effective for use in the patch. Generally, agents lacking either acid or ester moieties on the R' substituent were most effective.
- the most preferred compounds are those wherein R' is an alkyl ether wherein R' is an alkyl ether such as methoxy, ethoxy, propoxy or butoxy or a silyl ether such as tri ethylsilyl ether or triethylsilyl ether.
- a solution was prepared containing 8 ml of absolute ethanol, 32 ml dimethyl phthalate and 0.8 gm. of the test compound.
- a gel was formulated by gradual addition of 4 gm. of ethylcellulose to the solution. Stirring was continued until a clear solution was formed.
- the preparation had a consistency of a thin gel with a volume of 45 ml and a drug concentration of 18 mg/ml.
- mice were determined in CD/1 Swiss outbred four-week-old mice weighing 20 g. These mice were maintained at 84° F and fed Purina mouse chow and water ad libidum. The mice were infected with 5.98 x 10 5 P. bercfhei-parasitized mouse erythrocytes injected intraperitoneally. The day of inoculation was defined as day 0, with treatment days being counted in relation to that day. Assessment of the curative properties of a dosage regimen was made by comparing the survival times of treated mice with those of the untreated controls. The untreated mice died on either day 6 or 7.
- a dosage regimen was considered to be curative if the treated mice survived to day 60 and active if the survival time of the treated mice was greater than twice that of the controls, i.e., 12-14 days.
- blood films were taken immediately before drug application and on days 1-7 and thereafter weekly until day 60. Newly positive para- sitemias and deaths that occurred after 12-14 days were attributed to recrudescences. Mice designated cured had a negative parasitemia on day 60.
- Prophylactic properties of the drug regimens were appraised by comparison of survival times of mice that were treated on day 0 with those of infected, untreated controls.
- a dosage regimen was considered to have prophylactic activity (i.e., no infection was established) if the treated mice survived to day 60 and to be active if the survival time of the treated mice was greater than twice that of the untreated control mice, i.e., 12-14 days.
- Mouse parasitemias were determined on those days as described in the previous para ⁇ graph.
- mice that survived 60 days postinfection were inoculated with P. ber hei (5.98 x 10 5 parasitized erythro- cytes) to determine if they were completely cured. If the mice were susceptible to reinfection, they were considered to be totally parasite-free and subsequently to have lost their premunition type of immune status.
- P. ber hei 5.98 x 10 5 parasitized erythro- cytes
- mice Five mice were used in each test group- and each mouse received the formulation twice a day for 3 consecutive days. Although all of the gell appeared to be absorbed within eight hours, the bare skin was cleaned with 70% isopropyl alcohol before being re-treated. Mice were treated twice a day—in the morning and 8 or 12 hours later. Although the mice were not observed to lick the applied medication from their own backs or from the backs of the other treated mice, animals were housed in individual cages to avoid possibility of such activity.
- the transdermal formulation When the transdermal formulation was evaluated as a curative agent, the gel was applied beginning on day 3, when the parasitemias in the mice were typically 15%. When the formulation was evaluated for its prophylactic activity, it was typically applied 0.5 hours after inoculation with the parasite. Table I gives data relating to curative treatment. Table II give data related to prophylactic use.
- Example 2 Transdermal application using a patch
- mice Male mice (CD-I) used were 5 weeks old and weighted 20 gm on day 0. The fur was carefully removed with a hair clipper from the backs of mice from both the left and right sides between the hip and shoulder blade to give a denuded area of approximately 3 cm x 3 cm. The skin had no cut or abrasions. The mice were inoculated intraperitoneally with 5.98 x 10 5 parasites of Plasmodium berghei. Within 1/2 hour after infection, one group of mice was treated with the active agents applied directly to the skin. The gel was applied with a gloved finger and rubbed. For another group, the active agents were applied to a patch.
- the patches with the medicinals applied thereto were then affixed to the denuded skin area, where they remained for 24 hours.
- the mice were housed individually. The three doses were administered at 24 hour intervals. The mice were followed for 60 days. Infected, non- treated control mice and vehicle control mice routinely died within 7 or 8 days postinfection. Mice surviving 60 days were considered cured.
- Table III agent each dose total dose patch day of cured/prolonged mg mg Y/N death
- the active agent may be effectively prepared in any manner that will effectively cause the active agent to be placed on the support and, after application of the support surface to the skin, deliver the active agent to the skin.
- the active agent may be dissolved in carrier material containing DMSO and alcohol, then applied to a patch.
- the antimalarials in solution may be added to another carrier such as glycerol before application of the composition to the support material of the patch.
- U.S. Patent 4,978,532 describes use of patch technology. That reference is incorporated herein by reference.
- the patch may, for example, be a discoid in which a pressure-sensitive silicone adhesive matrix containing the active agent may be covered with a non-permeable backing.
- the discoid may either contain the active agent in the adhesive which can also act as a support or may have attached thereto a support made of material such as polyurethane foam, cellulose or gauze that will hold the active agent.
- the active agents incorporated into a solid support and applied to the skin can release the medicinal to provide sustained release to effect more cinsistent levels of the agent.
Abstract
L'invention concerne des antipaludiques du type artémisinine qui sont efficaces lorsqu'ils sont administrés par voie transdermique à des mammifères en doses d'environ 0,1 mg/kg à 60 mg/kg. Chez les mammifères tels que l'homme, le dosage est d'environ 0,1 mg/kg à 30 mg/kg dans le timbre. Les agents antipaludiques sont administrés par voie transdermique pour produire une réponse systémique. Lorsqu'ils sont administrés de cette manière, les agents actifs sont utiles à la fois pour la prophylaxie et le traitement du paludisme.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25861794A | 1994-06-16 | 1994-06-16 | |
US08/258,617 | 1994-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995034262A1 true WO1995034262A1 (fr) | 1995-12-21 |
Family
ID=22981376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/007696 WO1995034262A1 (fr) | 1994-06-16 | 1995-06-16 | Traitement transdermique du paludisme |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1995034262A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1150984A1 (fr) * | 1999-01-12 | 2001-11-07 | Hauser, Inc. | Composes dimeres de trioxane presentant des activites antiproliferative, et antitumorale |
US6692918B2 (en) | 1999-09-13 | 2004-02-17 | Nugen Technologies, Inc. | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
WO2007045116A1 (fr) * | 2005-10-20 | 2007-04-26 | Epipharm Gmbh | Traitement et prevention de manifestations pigmentaires (naevus) benignes grace a l'utilisation d'artemisinine et de ses derives |
WO2008037176A1 (fr) * | 2006-09-29 | 2008-04-03 | Beijing Zhongyan Tongrentang Chinese Medicine R & D Co., Ltd. | Préparations transdermiques comprenant de l'artémisinine et/ou ses dérivés |
CN101125135B (zh) * | 2007-08-22 | 2010-05-19 | 昆明制药集团股份有限公司 | 蒿甲醚巴布剂 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4438258A (en) * | 1981-06-12 | 1984-03-20 | National Research Development Corporation | Hydrogels |
US4791135A (en) * | 1987-08-20 | 1988-12-13 | The United States Of America As Represented By The Secretary Of The Army | Novel antimalarial dihydroartemisinin derivatives |
US4978676A (en) * | 1987-07-31 | 1990-12-18 | Thornfeldt Carl R | Treatment of skin diseases with artemisinin and derivatives |
US5130139A (en) * | 1990-07-06 | 1992-07-14 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5219865A (en) * | 1987-05-08 | 1993-06-15 | Hoechst Aktiengesellschaft | Pharmaceutical combination for the prophylaxis and therapy of malaria |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
-
1995
- 1995-06-16 WO PCT/US1995/007696 patent/WO1995034262A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4438258A (en) * | 1981-06-12 | 1984-03-20 | National Research Development Corporation | Hydrogels |
US5219865A (en) * | 1987-05-08 | 1993-06-15 | Hoechst Aktiengesellschaft | Pharmaceutical combination for the prophylaxis and therapy of malaria |
US4978676A (en) * | 1987-07-31 | 1990-12-18 | Thornfeldt Carl R | Treatment of skin diseases with artemisinin and derivatives |
US4791135A (en) * | 1987-08-20 | 1988-12-13 | The United States Of America As Represented By The Secretary Of The Army | Novel antimalarial dihydroartemisinin derivatives |
US5130139A (en) * | 1990-07-06 | 1992-07-14 | Alza Corporation | Reduction or prevention of skin irritation by drugs |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1150984A1 (fr) * | 1999-01-12 | 2001-11-07 | Hauser, Inc. | Composes dimeres de trioxane presentant des activites antiproliferative, et antitumorale |
EP1150984A4 (fr) * | 1999-01-12 | 2002-06-19 | Hauser Inc | Composes dimeres de trioxane presentant des activites antiproliferative, et antitumorale |
US6692918B2 (en) | 1999-09-13 | 2004-02-17 | Nugen Technologies, Inc. | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
WO2007045116A1 (fr) * | 2005-10-20 | 2007-04-26 | Epipharm Gmbh | Traitement et prevention de manifestations pigmentaires (naevus) benignes grace a l'utilisation d'artemisinine et de ses derives |
JP2009523703A (ja) * | 2005-10-20 | 2009-06-25 | エピフアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | アルテミシニン及びその誘導体を使用する良性色素性ホクロ(母斑)の処置及び予防 |
US8013011B2 (en) | 2005-10-20 | 2011-09-06 | Epipharm Gmbh | Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof |
AU2006303809B2 (en) * | 2005-10-20 | 2012-11-15 | Epipharm Ag | Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof |
WO2008037176A1 (fr) * | 2006-09-29 | 2008-04-03 | Beijing Zhongyan Tongrentang Chinese Medicine R & D Co., Ltd. | Préparations transdermiques comprenant de l'artémisinine et/ou ses dérivés |
CN101125135B (zh) * | 2007-08-22 | 2010-05-19 | 昆明制药集团股份有限公司 | 蒿甲醚巴布剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101173159B1 (ko) | 알칼로이드 제형 | |
US6974588B1 (en) | Transdermal patch for delivering volatile liquid drugs | |
JP5806287B2 (ja) | 経皮送達パッチ | |
US20030072814A1 (en) | Topical pharmaceutical composition for the treatment of warts | |
EP1137406A2 (fr) | Timbre transdermique pour administrer des medicaments liquides volatiles | |
EP1063981B1 (fr) | Utilisation de selegiline ou de desmethylselegiline pour traiter les plaies, les brulures et les lesions cutanees | |
US20020128326A1 (en) | Topical immunomodulating compositions for treatment of aids, hepatitis b&c, other infectious diseases, and cancer | |
WO1995034262A1 (fr) | Traitement transdermique du paludisme | |
JP2002534460A (ja) | モルヒネ又はモルヒナン型アルカロイドの有機酸付加塩を含む自己粘着性基質による経皮吸収治療システム | |
US6696078B1 (en) | System and methods for local intradermal treatment | |
US5559107A (en) | Regulation of immune response | |
FR2556216A1 (fr) | Nouveau medicament analgesique contenant du proglumide, eventuellement en association avec des medicaments analgesiques-narcotiques | |
WO2011035120A2 (fr) | Composition thérapeutique pour traiter des lésions provoquées par le virus herpès simplex | |
Ramesh | Treatment of post-kala-azar dermal leishmaniasis. | |
KR20140107389A (ko) | 상피의 관통 및 세포의 생물학적 이용률을 증가시키도록 화학적으로 개질된 광역학적 치료용 조성물 | |
CZ289788B6 (cs) | Topický přípravek pro zavádění peptidických farmak do ľivých organismů | |
CN106432226B (zh) | 1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药 | |
JP2004500315A5 (fr) | ||
RU2147440C1 (ru) | Обезболивающее и противозудное средство | |
Vardy et al. | Unusually extensive disease caused by Leishmania major parasites | |
MXPA06009912A (en) | Alkaloid formulations | |
MXPA00009098A (en) | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage | |
GB2482431A (en) | Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of a fluke infestation | |
MXPA97007811A (es) | Una composicion farmaceutica que contiene n-clorofenilcarbamatos, n-clorofeniltiocarbamatos y derivados de n-fosfonoglicina para inhibir el crecimiento de canceres y virus en mamiferos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |